Revvity (RVTY) AI Stock Analysis

• Market Cap: $11.80B
• Dividend Yield: 0.27%
• Average Volume (3M): 1.05M
• Price to Earnings (P/E): 40.5
• Beta (1Y): 0.66
• Revenue Growth: 1.62%
• EPS Growth: 78.53%
• Country: US
• Employees: 11,000
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.01
• Shares Outstanding: 117,869,660
• 10 Day Avg. Volume: 916,210
• 30 Day Avg. Volume: 1,048,689
• PEG Ratio: 6.29
• Price to Book (P/B): 1.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 21.36
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: 1.22
• Enterprise Value/Gross Profit: 8.59
• Enterprise Value/Ebitda: 4.03
• 1Y Price Target: $116.27
• Price Target Upside: 14.55% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 15

• Rating: 68 Neutral
• Price Target: $105.00 ▲(3.45%Upside)

Revvity's overall score reflects a stable financial position and positive earnings call highlights, including organic growth and successful cost mitigation strategies. However, high valuation metrics and technical indicators suggest caution. The company's ability to navigate academic market challenges and tariff pressures will be crucial for future performance.

Positive Factors

Operational Strategy

Revvity demonstrates agility in mitigating risks such as government funding cuts and tariffs.

Performance and Guidance

Management's ability to maintain guidance despite various challenges points to the conservatism in the initial outlook and the resilience of the business.

Resilience and Risk Mitigation

Revvity, Inc.'s transformed portfolio is expected to be resilient through ongoing market turbulence.

Negative Factors

Growth Challenges

Expectations for Life Sci Instruments have been lowered, which is causing a headwind to the company's top-line growth.

Profitability Concerns

The margin outlook slightly decreased, indicating potential challenges in maintaining profitability.

Research and Development

Concerns persist over spending on early-stage research, which could impact future growth.

Revvity Business Overview & Revenue Model

Company Description

Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

How the Company Makes Money

Revvity generates revenue through the sale of its diverse portfolio of products and services. The company's key revenue streams include the manufacturing and distribution of healthcare equipment, industrial machinery, and consumer products. Additionally, Revvity engages in strategic partnerships and collaborations that enhance its market presence and drive sales growth. By focusing on innovation and customer satisfaction, Revvity maintains a competitive edge, ensuring steady income from both longstanding and new business relationships.

Revvity Financial Statement Overview

Summary

Revvity's financial performance is stable with strong cash flow management and a solid balance sheet, as indicated by a robust cash flow score of 75. However, challenges in revenue growth and declining profitability margins noted in the income statement score of 65 impact the overall financial performance score.

Income Statement

Revvity's income statement shows a mixed performance. The revenue has seen a slight increase in the TTM, but a significant decline when compared to previous years, indicating a concerning trend in revenue growth. The gross profit margin is strong at 56.3% for TTM, but net profit margin has decreased to 11.2%, indicating rising costs or inefficiencies. EBIT and EBITDA margins have also seen a decline from previous years. Overall, profitability is under pressure but remains relatively stable for the industry.

Balance Sheet

The balance sheet indicates a solid equity position with a debt-to-equity ratio of 0.44 and an equity ratio of 61.8% for TTM, suggesting financial stability and a conservative capital structure. Return on equity has decreased, reflecting the net income decrease, but remains acceptable at 4.05%. The decrease in total assets over time suggests potential divestments or asset efficiency improvements.

Cash Flow

Cash flow statements show strong free cash flow generation with a positive free cash flow to net income ratio. Operating cash flow to net income ratio is healthy, indicating good cash conversion. Despite a dip in operating and free cash flow in the TTM period, cash flow management appears robust, with a focus on maintaining liquidity and managing capital expenditures efficiently.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.77B	2.76B	2.75B	3.31B	3.83B	2.66B
Gross Profit	1.56B	1.54B	1.54B	1.99B	2.43B	1.74B
EBITDA	846.87M	840.25M	713.56M	1.18B	1.73B	1.20B
Net Income	286.61M	270.38M	693.09M	569.18M	943.16M	727.89M
Balance Sheet
Total Assets	12.36B	12.39B	13.56B	14.13B	15.00B	7.96B
Cash, Cash Equivalents and Short-Term Investments	1.14B	1.16B	1.60B	454.36M	603.32M	402.04M
Total Debt	3.33B	3.30B	4.07B	4.60B	5.16B	2.22B
Total Liabilities	4.72B	4.73B	5.69B	6.75B	7.86B	4.22B
Stockholders Equity	7.64B	7.67B	7.87B	7.38B	7.14B	3.74B
Cash Flow
Free Cash Flow	524.11M	541.65M	9.90M	594.18M	1.32B	814.67M
Operating Cash Flow	608.89M	628.30M	91.27M	679.81M	1.41B	892.18M
Investing Cash Flow	787.97M	776.16M	1.31B	-132.85M	-4.11B	-504.50M
Financing Cash Flow	-1.26B	-1.13B	-947.12M	-661.80M	2.94B	-202.87M

Revvity Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 101.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RVTY, the sentiment is Positive. The current price of 101.5 is above the 20-day moving average (MA) of 97.81, above the 50-day MA of 94.58, and below the 200-day MA of 109.09, indicating a neutral trend. The MACD of 1.97 indicates Negative momentum. The RSI at 60.44 is Neutral, neither overbought nor oversold. The STOCH value of 70.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for RVTY.

Revvity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DGX	73 Outperform	$19.38B	21.67	13.35%	1.84%	9.38%	6.43%
QGEN	72 Outperform	$10.39B	116.32	2.67%	2.72%	3.31%	-72.63%
MEDP	72 Outperform	$9.22B	25.05	65.82%	―	9.87%	32.81%
RVTY	68 Neutral	$11.80B	40.49	3.82%	0.27%	1.62%	78.53%
NTRA	68 Neutral	$22.09B	―	-18.66%	―	51.50%	53.23%
ILMN	58 Neutral	$15.84B	―	-23.82%	―	-3.47%	25.55%
Sector *	52 Neutral	$7.59B	0.30	-61.86%	2.27%	16.72%	1.10%

Revvity Corporate Events

Revvity to Announce Q4 and Full-Year 2024 Results

Revvity announced it will release its fourth quarter and full-year 2024 financial results on January 31, 2025, followed by a conference call led by CEO Prahlad Singh and CFO Max Krakowiak. The company expects fourth-quarter revenue growth of approximately 5% to 6% and anticipates meeting or exceeding its full-year 2024 adjusted earnings per share guidance. Revvity is also set to present at the J.P. Morgan Healthcare Conference, where it will discuss these financial results and future projections, reflecting its strong positioning in the healthcare industry.